放射性藥物領域的成長機會

大型製藥企業日益成長的興趣推動了行業創新動力。

本報告涵蓋診斷放射學（包括PET、SPECT）和放射性藥物（包括α療法、BETA療法、Auger療法和治療診斷學）的臨床試驗評估。報告還涵蓋了各領域的主要企業及其在放射性藥物行業中扮演的角色。

本報告重點在於能夠提昇放射性藥物性能的技術創新。放射性藥物產業目前正處於高信心階段的初期，投資者、合約研發生產機構（CDMO）和大型製藥企業積極參與資金籌措、授權合約、收購和策略聯盟等活動。本研究深入分析了有助於放射性藥物產業發展的夥伴關係、協作、併購以及私人資金籌措活動。

本報告解答的關鍵問題包括：

• 放射性藥物研發的關鍵促進因素和挑戰是什麼？
• 各細分市場的臨床研發進度如何？
• 哪些是研發創新放射性藥物的關鍵產業參與者？
• 放射性藥物的資金籌措合作環境如何？
• 放射性藥物有哪些成長機會？

目錄

戰略問題

• 為什麼經濟成長變得越來越困難？
• The Strategic Imperative 8
• 三大戰略挑戰對產業的影響
• 成長引擎由成長機會驅動
• 調查方法

成長機會分析

• 分析範圍
• 區隔

成長要素

• 成長促進因素
• 成長抑制因素
• 引言：放射性藥物正日益受到關注

放射診斷

• 放射診斷
• 腫瘤學中的PET分析
• 用於PET成像的放射性藥物
• SPECT放射診斷分析
• 關鍵創新：放射學

放射治療藥物

• 放射治療藥物
• 放射線治療的比較分析
• 放射治療產品線概覽
• 放射性藥物的關鍵趨勢
• 放射性藥物：創新者聚焦
• 放射性藥物的技術創新
• 標靶化策略和放射化學的進展：創新
• 新型放射性同位素：創新
• 藥物輸送技術：創新

戰略洞察

• 放射治療藥物的私人資金籌措
• 放射性藥物收購趨勢概述
• 放射性藥物的合作關係
• 關鍵見解
• 全球併購和聯盟趨勢
• 世界地圖上的放射性藥物公司
• 來自放射性藥物專家的見解

成長機會領域

• 成長機會1：致力於Alpha療法
• 成長機會2：聚焦放射治療藥物
• 成長機會3：致力於新目標

附錄

• 用於PET成像的放射性藥物
• 主要產業公司臨床研發管線分析：放射治療
• 技術成熟度等級（TRL）解釋

未來計劃

• 成長機會帶來的益處和影響
• 未來計劃
• 免責聲明

Emerging Interest from Big Pharma Players Is Pushing Industry Innovation Momentum

The report covers the clinical trial assessment for radiodiagnostics, including PET, SPECT, and radiopharmaceuticals, comprising Alpha therapy, Beta therapy, Auger Therapy, and Theranostics. The report covers the key players in each space and their contributions to the radiopharmaceuticals landscape.

The report sheds light on technology innovations to make better radiopharmaceuticals. The radiopharmaceuticals industry is at the cusp of a high-confidence phase, with investors, CDMOs, and big pharmaceutical firms engaging in fundraising rounds, licensing agreements, acquisitions, and strategic collaborations. This research provides insights into partnerships, collaborations, acquisitions/mergers, and private funding activities that contribute to the growth of radiopharmaceuticals.

Key questions this report answers: What are the key drivers and challenges for the development of radiopharmaceuticals? What is the pace of clinical development in each segment? Who are the leading industry participants developing innovative radiopharmaceuticals? What does the funding and partnership landscape look like for radiopharmaceuticals? What are the growth opportunities in radiopharmaceuticals?

Table of Contents

Strategic Imperatives

• Why Is It Increasingly Difficult to Grow?
• The Strategic Imperative 8
• The Impact of the Top 3 Strategic Imperatives on the Industry
• Growth Opportunities Fuel the Growth Pipeline Engine
• Research Methodology

Growth Opportunity Analysis

• Scope of Analysis
• Segmentation

Growth Generator

• Growth Drivers
• Growth Restraints
• Introduction: Radiopharmaceuticals Gaining Traction

Radiodiagnostics

• Radiodiagnostics
• PET Analysis for Oncology
• PET Imaging Radiopharmaceuticals
• SPECT Analysis for Radio Diagnostics
• Key Innovators-Radiodiagnostics

Radiotherapeutics

• Radiotherapeutics
• Comparative Analysis of Radiotherapies
• Overview of the Radiotherapeutics Pipeline
• Key Trends in Radiopharmaceuticals
• Radiopharmaceuticals-Innovator Spotlight
• Technological Innovation in Radiopharmaceuticals
• Targeting Strategies and Radiochemistry Advances-Innovations
• Novel Radioisotopes-Innovations
• Drug Delivery-Innovations

Strategic Insights

• Private Funding for Radiotherapeutics
• Overview of the Acquisition Landscape for Radiopharmaceuticals
• Partnership Landscape in Radiopharmaceuticals
• Key Insights
• Global M&A; Partnerships Landscape
• Radiopharma Companies on Global Map
• Insights from Radiopharmaceuticals Experts

Growth Opportunity Universe

• Growth Opportunity 1: Focus on Alpha Therapies
• Growth Opportunity 2: Focus on Radiotherapeutics
• Growth Opportunity 3: Focus on Novel Targets

Appendix

• PET Imaging Radiopharmaceuticals
• Clinical Pipeline Analysis of Key Industry Players-Radiotherapeutics
• Technology Readiness Levels TRL: Explanation

Next Steps

• Benefits and Impacts of Growth Opportunities
• Next Steps
• Legal Disclaimer